Natural history of the revised ALS functional rating scale and its association with survival: the PRECISION-ALS Extant Study

Functional loss in ALS follows a decelerating trajectory, where the current functional status and the rate of change have a direct impact on the patient' s probability of survival. Given the pivotal role of the ALSFRS-R in drug development, these results help to separate treatment benefit from the disease's natural trajectory and to estimate the impact on survival.

Authors

Institutions

Publication Details

Journal
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Published
2025-05-06
DOI
https://doi.org/10.1080/21678421.2024.2443985
Citations
5
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
6.95

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Natural history of the revised ALS functional rating scale and its association with survival: the PRECISION-ALS Extant Study

Carlos Pastor‐Vargas, Philip Van Damme, Miriam Galvin, Mark Heverin et al.
5 citations
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Amyotrophic Lateral Sclerosis Research
6.95
article

Natural history of the revised ALS functional rating scale and its association with survival: the PRECISION-ALS Extant Study

Carlos Pastor‐Vargas, Philip Van Damme, Miriam Galvin, Mark Heverin, Fouke Ombelet, Nikita Lamaire, Christopher J. McDermott, Sarah Opie-Martin, Ruben P. A. van Eijk, Umberto Manera, Caroline Ingre, Harry McDonough, Rosario Vasta, Leonard H. van den Berg, Jordi W. J. van Unnik, Stefan Sennfält, Robert McFarlane, Pamela J. Shaw, Éanna Mac Domhnaill, Daphne N. Weemering, Frederik Hobin, Philippe Corcia, Jan H. Veldink, Adriano Chiò, Mónica Povedano Panadés, Alejandro Caravaca Puchades, Oskar Holmdahl, Mohammed Mouzouri
article en
5 citations

Abstract

Functional loss in ALS follows a decelerating trajectory, where the current functional status and the rate of change have a direct impact on the patient' s probability of survival. Given the pivotal role of the ALSFRS-R in drug development, these results help to separate treatment benefit from the disease's natural trajectory and to estimate the impact on survival.

Amyotrophic Lateral Sclerosis and Frontotemporal DegenerationVol. 26(sup1)
Université de Tours (FR), Karolinska University Hospital (SE), Inserm (FR), King's College London (GB), Trinity College Dublin (IE), Bellvitge University Hospital (ES), Karolinska Institutet (SE), University Medical Center Utrecht (NL), Institut d'Investigació Biomédica de Bellvitge (ES), Centre Hospitalier Universitaire de Tours (FR), Laboratoire National de Référence (MA), Neuroscience Institute (IT), King's College Hospital (GB), VIB-KU Leuven Center for Brain & Disease Research (BE), University of Turin (IT), Oklahoma State University Center for Health Sciences (US), University of Sheffield (GB), KU Leuven (BE)
Biogen, Motor Neurone Disease Research Institute of Australia, South London and Maudsley NHS Foundation Trust, MND Scotland, LifeArc, National Institute for Health and Care Research, Motor Neurone Disease Association, King's College London, Fonds Wetenschappelijk Onderzoek, KU Leuven, Vlaamse regering, Medical Research Council
Openalex Percentile: Top 3%
Amyotrophic Lateral Sclerosis Research
6.95
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.